RxDoctor Payments DataLook up a doctor →

Matthew Gilbert, DO

Endocrinology, Diabetes & Metabolism · South Burlington, VTNPI 1073634531

Payments from drug & device makers

$429,653in general payments, 2019–2025

Across 1,014 payments — averaging $423.72 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk AS$294K
  • AbbVie$60K
  • Novo Nordisk$58K
  • Sanofi US Services Inc.$13K
  • Corcept Therapeutics$4K
  • Eli Lilly$382
  • plus $121 from 2 others
$3,521in research payments, 2019–2025

Across 16 payments — averaging $220.04 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Novo Nordisk AS$3K
  • Eli Lilly$535
  • Novo Nordisk$25

General payments by program year

19
20
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

Too few endocrinology, diabetes & metabolism providers in Vermontto place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$33,308
Medicare patients
227
Services billed
422

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other endocrinology, diabetes & metabolism in South Burlington

See the full list for Vermont

Where these figures come from

Is this you, or does something look wrong? →